Competitive comparison. Thirty-nine test samples were run on Vendor A's 39-plex and compared to the same overlapping 39 analytes in the Bio-Plex Pro Human Cytokine 48-Plex Screening Panel. This test configuration generated 1,521 total possible data points (39 samples x 39 analytes). In total, Vendor A's assay detected 637 data points within their working assay range while the 39 analytes from the Bio-Plex Pro Panel detected 1,140 data points. Detected data points divided by total possible data points defines analyte detectability in this comparison. Analyte detectability for Vendor A (■) is 42% while analyte detectability for the Bio-Plex Pro Panel (■) is 75%. Bio-Rad offers 79% improved analyte detectability over Vendor A in the context of these 39 overlapping targets.